Natural Opioids Linked to Chronic Pain

The body’s own pain-quelling system may be at the root of chronic pain and symptoms of opioid withdrawal, according to a new study in mice.

Written byJef Akst
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

FLICKR, WOODLEYWONDERWORKSWhen the body suffers an acute injury, it releases natural opioid compounds that have an immediate analgesic effect, making painful accidents much more tolerable. But that pain-reducing system may be a double-edged sword, according to a mouse study published today (September 19) in Science: the process appears to switch a natural opioid receptor into a chronically “on” position; flipping it back “off” leads to a resurgence of pain in the animals, even months after the initial injury. Moreover, the pain behaviors that resurfaced when the receptor was turned off looked strikingly like those associated with opioid withdrawal.

“You have the same system, the same structure, involved in both the effect of analgesia—in reducing pain sensation—and in opioid dependence and chronic pain,” said neurobiologist Flaminia Pavone of the Cell Biology and Neurobiology Institute in Italy, who was not involved in the work. “[It’s] a paradoxical effect that can lead to more sensitivity to pain.”

Chronic pain can arise following acute injuries. Chronic back pain, for example, is often preceded by lower back injuries. When and why acute pain is translated into chronic pain, however, is largely unknown. Sensory neurobiologist Bradley Taylor from the University of Kentucky Medical Center and his colleagues wondered whether the answer might lie in the body’s mechanisms for controlling pain in the first place. “We know that the body ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies